Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of SR123781A vs enoxaparin for prevention of venous thromboembolism after elective total hip replacement
2006-000152-41Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2006
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sr-123781a in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Sanofi. Primary endpoint: Composite venous thromboembolism endpoint. Started Mar 2006; status: completed.
02
Drugs
sr-123781a
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2006-000152-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000152-41.